CNS Pharmaceuticals regains Nasdaq equity compliance after $9.9M share sale

CNS Pharmaceuticals, Inc.

Shareholders' equity exceeds $5.0M, above Nasdaq's $2.5M minimum for continued listing.
Sold 23,091,315 shares under A.G.P. agreement for gross proceeds of ~$9.9M.
Cash on deposit $9.6M; company expects to fund operations through Q1 2025.
Nasdaq Panel had granted final extension to Aug 12, 2024; delisting risk now resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.